US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security
The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the...
Company
Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q1 2025 revenues of USD...
BMS Faces Phase III Setback for Camzyos in Non-Obstructive HCM Study
US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has reported a setback in the Phase...
Beijing Wantai Launches Phase III Trial for 9-Valent HPV Vaccine in Chinese Males
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has initiated a Phase III...
Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA₂ Inhibitor for Alzheimer’s Disease
China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) has announced the initiation of a Phase...
Hengrui Pharmaceuticals Gains NMPA Clearance for Phase II Study of HRS-7058 in Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced clearance from the National Medical...
Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its...
Roche’s Columvi Approved by EC for Relapsed DLBCL Treatment in Europe
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that it has received marketing...
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-1819 in Allergic Rhinitis Study
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received approval...
CSPC Pharmaceutical Gains FDA Approval for SYS6041 ADC in Advanced Solid Tumors
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...
Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases
Germany’s Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc....
Peijia Medical’s TaurusTrio TAV System Accepted for NMPA Review in China
China-based Peijia Medical Ltd (HKG: 9996) has announced that the National Medical Products Administration (NMPA)...
HighTide Therapeutics’ HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment
China-based HighTide Therapeutics Inc. (HKG: 2511) has announced positive results from two Phase III clinical...
Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259
China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance...
Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production
Novlead Biotech, a Nanjing-based specialist in nitric oxide (NO) gas detection and treatment, has secured...
Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters
UK-headquartered Chromatin Bioscience has entered into a collaboration with Japan-based Astellas Pharma Inc. (TYO: 4503)...
MSD’s Gardasil 9 Approved in China for Males Aged 16 to 26
US pharmaceutical major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced marketing approval from...
Mabwell and DP Technology Collaborate to Build Biopharma AI Platform for Drug Development
Chinese companies Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) and DP Technology have entered into...
Bristol-Myers Squibb Wins FDA Approval for Opdivo-Yervoy Combo in First-Line HCC Treatment
Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another indication approval from the US Food and...
Jiangxi Institute of Biological Products Files for Hong Kong IPO Amid Strong Market Position
Jiangxi Institute of Biological Products Inc., China’s largest provider and exporter of human tetanus antitoxin...